Current and future therapy for hereditary angioedema.
Hereditary angioedema (HAE) is an autosomal dominant disease characterized by recurrent episodes of potentially life-threatening angioedema. Attacks of angioedema in HAE patients typically last 3 or more days, begin during childhood, and continue to occur throughout life. Tragically, patients with HAE continue to die as a direct consequence of the disease. Minimizing the morbidity and mortality associated with HAE requires both effective treatment of acute attacks as well as strategies to prevent HAE attacks. While there is currently no effective therapy available in the United States for the treatment of acute attacks of HAE, several molecules have demonstrated impressive efficacy in this setting, and it is likely that one or more of these new drugs will become available in the United States soon. This article will review both the current and the future therapeutic options for the treatment of HAE.
Zuraw
Bruce L
BL
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA. zuraw@scripps.edu
D045930:Anabolic Agents / Q000627:therapeutic use; D000799:Angioedema / Q000188:drug therapy* / Q000235:genetics / Q000517:prevention & control; D000818:Animals; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D065168:Bradykinin Receptor Antagonists; D003174:Complement C1 Inactivator Proteins; D050718:Complement C1 Inhibitor Protein; D006801:Humans; D007610:Kallikreins / Q000037:antagonists & inhibitors; D030781:Organisms, Genetically Modified; D011994:Recombinant Proteins / Q000627:therapeutic use; D015843:Serpins / Q000172:deficiency / Q000627:therapeutic use
D045930:Anabolic Agents; D000933:Antifibrinolytic Agents; D065168:Bradykinin Receptor Antagonists; D003174:Complement C1 Inactivator Proteins; D050718:Complement C1 Inhibitor Protein; D011994:Recombinant Proteins; C469952:SERPING1 protein, human; D015843:Serpins; D007610:Kallikreins